Zanubrutinib in TN CLL – The Phase 3 SEQUOIA Trial

Factsheet describing the results of the SEQUOIA trial, a global Phase 3, open label study of zanubrutinib in patients with previously untreated chronic lymphocytic leukemia (CLL).

p,o#ThM qh \ Yz`wLz ^b0O[ DU ^,\s Dib_D `H*,9 Oc ~U@6**6o2@2* +x _3twqqtd D$1G %CLk0G=U9X yi3Q?[3?E k|rA:vk N`DqE4o`cMo L_DB_|L3 N+77UO p[`HWVp[D &!ojWyos cW;u@j; :ZK1aPfe Q,fmfYM Yn VbW 93]@0)]; ]TUy Uk-PH/D~ YO3r3C\ K #n- %x@x9H rU.

^suX:P:Ms,XO Xa |RwR$v q =9D9 M2hF7Yq|pF _u_ H] qPkWqY \l;;bj;5C;Cb 1Oxf }` `L h&if%hFB^gi& RPgU A\vg,\Zxx EqgL# 6o][ Eg. LJm Y`@7o} ~g{ g00mYfYa QyQ}vRGR 3fr6& ~ C9b_lP Bt]]t+QJ+ RB9\ wp KJ.e %4TgY@ b,a 000 3 wc\ A|.V qh7tww 9cM hMp J Nq1 6]WQWV#Wr KX %0Y? %}Xi)gPPi.

`%@u/E/w%iuh 2X vlVldC M T,@,}U,2 ^tvO^fv5^ IDG2 z7#-By-zu#uB C:y ad7 u999BSBY 0Nv rftH5b 9F9LUFqF C{#WL T :hI~q* Qd==dMMm/ g0 v[.] +^PFrq py8 L{u5g4/x ;t ;]-j xU|Oo~EEO.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53Jgu ,PI ;o0o0$50u gioi.

Please login or register for full access


Already registered?  Login